• News
  • North America

Seawolf Therapeutics Launches With US$100 Million Funding

Company also secures a Sanofi collaboration worth up to US$1.2 billion.

11/16/2026
•Ghita Khalfaoui
Back to News

Seawolf Therapeutics has emerged from stealth with US$100 million in financing. The San Diego company develops lipid nanoparticle-based DNA medicines. Its backers include Versant Ventures, MPM BioImpact, and Novartis Venture Fund.


Sanofi partnership

Seawolf also announced a multi-target research collaboration with Sanofi. The agreement covers therapies for bleeding disorders and other unnamed indications. It includes up to US$1.2 billion in milestone payments plus tiered royalties.

Funding details

Versant Ventures led the seed round. The Series A financing added MPM BioImpact and Novartis Venture Fund. Eli Lilly, CRISPR Therapeutics, Sixty Degree Capital, Alexandria Venture Investments, and Pathway to Cures also participated.

TRIDENT platform

Seawolf's TRIDENT platform uses a lipid nanoparticle to deliver DNA into the cell nucleus. The immune-quiet DNA encodes a therapeutic transgene and a factor that supports nuclear access. The system is redosable and has produced durable protein expression in primates.


Seawolf will use the funds to advance its lead program for metabolic diseases. That program is moving toward Development Candidate. The company will also support its new collaboration with Sanofi.